Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$132.80
+0.6%
$130.19
$99.71
$141.23
$231.04B0.746.13 million shs3.08 million shs
AstraZeneca PLC stock logo
AZN
AstraZeneca
$70.87
+0.7%
$69.45
$61.24
$87.68
$219.79B0.45.17 million shs3.46 million shs
Novartis AG stock logo
NVS
Novartis
$112.47
+0.5%
$109.89
$96.06
$120.92
$237.58B0.61.59 million shs1.11 million shs
Sanofi stock logo
SNY
Sanofi
$52.35
+0.7%
$52.45
$45.80
$60.12
$132.25B0.552.39 million shs2.24 million shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abbott Laboratories stock logo
ABT
Abbott Laboratories
-0.65%-0.77%+1.96%-2.82%+29.53%
AstraZeneca PLC stock logo
AZN
AstraZeneca
-0.82%+1.00%+0.64%-6.97%-8.14%
Novartis AG stock logo
NVS
Novartis
-1.02%-0.81%-0.64%+2.73%+12.24%
Sanofi stock logo
SNY
Sanofi
-0.76%-1.72%-1.46%-3.97%+8.45%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Abbott Laboratories stock logo
ABT
Abbott Laboratories
4.866 of 5 stars
2.43.04.24.53.52.52.5
AstraZeneca PLC stock logo
AZN
AstraZeneca
2.2147 of 5 stars
2.63.01.70.02.90.01.3
Novartis AG stock logo
NVS
Novartis
2.3666 of 5 stars
1.05.02.50.04.00.01.9
Sanofi stock logo
SNY
Sanofi
3.5571 of 5 stars
2.63.02.50.03.30.03.1
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Abbott Laboratories stock logo
ABT
Abbott Laboratories
2.84
Moderate Buy$142.597.37% Upside
AstraZeneca PLC stock logo
AZN
AstraZeneca
3.10
Buy$88.0024.17% Upside
Novartis AG stock logo
NVS
Novartis
2.00
Hold$123.389.70% Upside
Sanofi stock logo
SNY
Sanofi
3.14
Buy$63.3320.98% Upside

Current Analyst Ratings Breakdown

Latest ABT, AZN, NVS, and SNY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/28/2025
Sanofi stock logo
SNY
Sanofi
Hsbc Global Res
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
4/17/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$133.00 ➝ $145.00
4/17/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$132.00 ➝ $142.00
4/17/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$140.00 ➝ $145.00
4/17/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$117.00 ➝ $127.00
4/17/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$136.00 ➝ $147.00
4/17/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$158.00 ➝ $159.00
4/17/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$135.00 ➝ $145.00
4/17/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold ➝ Hold$135.00 ➝ $137.00
4/15/2025
AstraZeneca PLC stock logo
AZN
AstraZeneca
BNP Paribas
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$75.00
4/15/2025
Novartis AG stock logo
NVS
Novartis
BNP Paribas
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$42.34B5.46$5.72 per share23.22$22.36 per share5.94
AstraZeneca PLC stock logo
AZN
AstraZeneca
$54.98B4.00$6.01 per share11.79$13.18 per share5.38
Novartis AG stock logo
NVS
Novartis
$53.22B4.46$11.21 per share10.03$21.59 per share5.21
Sanofi stock logo
SNY
Sanofi
$45.17B2.93$5.15 per share10.16$33.20 per share1.58
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$13.40B$7.7117.3623.182.5231.95%20.74%11.19%7/17/2025 (Estimated)
AstraZeneca PLC stock logo
AZN
AstraZeneca
$7.04B$2.4931.3614.171.4213.01%32.23%12.31%7/24/2025 (Estimated)
Novartis AG stock logo
NVS
Novartis
$11.94B$6.4019.1312.771.7023.56%37.24%15.85%7/17/2025 (Estimated)
Sanofi stock logo
SNY
Sanofi
$6.02B$2.8021.0211.021.0112.77%25.61%14.72%7/24/2025 (Estimated)

Latest ABT, AZN, NVS, and SNY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/29/2025Q1 2025
AstraZeneca PLC stock logo
AZN
AstraZeneca
$1.10$1.24+$0.14$0.93$13.71 billion$13.59 billion
4/29/2025Q1 2025
Novartis AG stock logo
NVS
Novartis
$2.12$2.28+$0.16$1.83$12.92 billion$13.23 billion
4/24/2025Q1 2025
Sanofi stock logo
SNY
Sanofi
$0.90$0.94+$0.04$0.80$9.79 billion$10.41 billion
4/16/2025Q1 2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$1.07$1.09+$0.02$0.76$10.38 billion$10.36 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$2.361.78%+7.17%30.61%54 Years
AstraZeneca PLC stock logo
AZN
AstraZeneca
$2.062.91%+1.98%82.73%N/A
Novartis AG stock logo
NVS
Novartis
$2.592.30%+5.34%40.47%N/A
Sanofi stock logo
SNY
Sanofi
$1.603.06%+1.84%57.14%N/A

Latest ABT, AZN, NVS, and SNY Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/15/2025
Sanofi stock logo
SNY
Sanofi
annual$2.03693.1%5/9/20255/9/20256/12/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.32
1.60
1.14
AstraZeneca PLC stock logo
AZN
AstraZeneca
0.65
0.93
0.74
Novartis AG stock logo
NVS
Novartis
0.48
1.04
0.84
Sanofi stock logo
SNY
Sanofi
0.15
1.46
1.14

Institutional Ownership

CompanyInstitutional Ownership
Abbott Laboratories stock logo
ABT
Abbott Laboratories
75.18%
AstraZeneca PLC stock logo
AZN
AstraZeneca
20.35%
Novartis AG stock logo
NVS
Novartis
13.12%
Sanofi stock logo
SNY
Sanofi
14.04%

Insider Ownership

CompanyInsider Ownership
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.46%
AstraZeneca PLC stock logo
AZN
AstraZeneca
N/A
Novartis AG stock logo
NVS
Novartis
0.01%
Sanofi stock logo
SNY
Sanofi
1.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Abbott Laboratories stock logo
ABT
Abbott Laboratories
115,0001.74 billion1.73 billionOptionable
AstraZeneca PLC stock logo
AZN
AstraZeneca
83,5003.10 billionN/AOptionable
Novartis AG stock logo
NVS
Novartis
101,7002.11 billion2.04 billionOptionable
Sanofi stock logo
SNY
Sanofi
91,6002.53 billion2.51 billionOptionable

Recent News About These Companies

Sanofi: Sanofi completes acquisition of DR-0201
Sanofi, VNVC launch vaccine factory in Vietnam
Press Release: Sanofi completes acquisition of DR-0201

New MarketBeat Followers Over Time

Media Sentiment Over Time

Abbott Laboratories stock logo

Abbott Laboratories NYSE:ABT

$132.80 +0.78 (+0.59%)
Closing price 03:59 PM Eastern
Extended Trading
$132.20 -0.60 (-0.45%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

AstraZeneca stock logo

AstraZeneca NASDAQ:AZN

$70.87 +0.49 (+0.70%)
Closing price 04:00 PM Eastern
Extended Trading
$71.00 +0.13 (+0.18%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Novartis stock logo

Novartis NYSE:NVS

$112.47 +0.60 (+0.54%)
Closing price 03:59 PM Eastern
Extended Trading
$111.25 -1.22 (-1.08%)
As of 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Sanofi stock logo

Sanofi NASDAQ:SNY

$52.35 +0.36 (+0.69%)
Closing price 04:00 PM Eastern
Extended Trading
$52.32 -0.02 (-0.05%)
As of 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.